BioSpace News Archive

The pre-defined disease control efficacy threshold in ovarian cancer was not met and this cohort will be closed for enrollment

Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, today announced that the first subject has been dosed in its Phase 1 study of VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate. “We are advancing VXA-CoV2-

Gain Therapeutics, Inc., (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced that it will present an oral poster on its brain penetrant structurally targeted allosteric regulators (STARs) for the treatment of neuronopathic Gaucher disease at the 14th Meeting of the European Working Group on Gaucher Disease (EWGGD) ,

Novavax, Inc. (Nasdaq: NVAX) Novavax, Inc. (Nasdaq: NVAX), today announced the formation of a leadership team to advance NanoFlu to regulatory licensure and the promotion of Russell (Rip) Wilson, J.D./M.B.A., to Executive Vice President and the newly-created role of NanoFlu™ General Manager.

Study Shows PixCell’s HemoScreen™ May Be Used to Monitor Pathological Blood Samples, Improving Treatment Process for Hematological Patients

Without directly invading the brain or nerves, the virus responsible for COVID-19 causes potentially damaging neurological injuries in about one in seven infected, a new study shows.

Visby Medical™, an infectious disease diagnostic company, received Phase 2 funding from the National Institutes of Health (NIH) as part of its Rapid Acceleration of Diagnostics (RADx) initiative. The RADx initiative aims to combat SARS-CoV-2 and increase national testing capacity for COVID-19.

Cedilla Therapeutics, a private biotechnology company developing targeted small molecules for the treatment of cancer and other diseases caused by protein dysregulation, today announced the closing of a $57.6 million Series B financing. The financing was co-led by Casdin Capital and Boxer Capital of Tavi

Shionogi Announces Publication of Two Studies in The Lancet Infectious Diseases Highlighting the Efficacy and Safety of FETROJA ® for the Treatment of Infections Due to Aerobic Gram-negative Bacteria in Adults With Limited Treatment Options Shionogi announces publication of data from two of its clinical trials; APEKS-NP and CREDIBLE-CR in the journal The Lancet Infectious Diseases APEKS-NP demonstrated that FETROJA (cefiderocol) is an effective a

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2020 financial results on Thursday, November 5, 2020. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, November 5, 2020 to discuss its third quarter 2020 financial results. The call may be accessed